-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Cellectis, Lowers Price Target to $8

Benzinga·09/15/2026 12:42:30
Listen to the news
Baird analyst Jack Allen maintains Cellectis (NASDAQ:CLLS) with a Outperform and lowers the price target from $10 to $8.